UNSPSC 51361910: Butobarbital or butobarbitone

This classification denotes a barbiturate with the molecular formula C10H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OHZ8QAW6YC, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-butyl-5-ethyl- (9ci) but generally known as butethal, which bears US NIH Compound Identifier 6473. Butethal most often comes in base and sodium forms. European Medicines Agency schedules Butobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13135MIG.

World Health Organization schedules butethal in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCCCC1(C(=O)NC(=O)NC1=O)CC.

UNSPSC 51361910 Butobarbital or butobarbitone is a Commodity code covering controlled pharmaceutical substances, but recent state and local solicitations tagged with this code show minimal alignment with the nominal scope—the three recent opportunities center instead on naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution through cooperative purchasing vehicles. The actual work being solicited under this code involves supply of pharmaceutical products through authorized wholesalers, competitive bidding for health-system inventory, and market research into alternative pharmacy benefit delivery models. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The code shows minimal recent activity and limited specificity to the butobarbital category itself; the mismatch between the code's nominal scope and the actual solicitations suggests either classification drift or limited current procurement volume in this specific controlled substance.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's reach extending to Oregon and other participating jurisdictions. Recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels; and MMCAP's Request for Proposal S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026. No budget ranges or award values are disclosed in the recent solicitations. The Seminole County bid includes federal compliance requirements tied to potential FEMA funding, and the MMCAP RFP imposes a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation.